Auricularia and Osteoblast Differentiation

Wood Ear Bone Health

Biphasic Activity

Auricularia extract simultaneously inhibits bone-resorbing osteoclasts and promotes bone-forming osteoblasts, a dual action relevant to osteoporosis research.

Kim et al., Journal of Microbiology and Biotechnology, 2024

BMP-2/Runx2/Smad

osteogenic pathway activated

59% IL-1 Reduction

largest of three bone-resorption genes lowered

2 Direct Bone Studies

plus 3 supporting studies; no human bone data

Kim et al., Journal of Microbiology and Biotechnology, 2024

View as image ↗

Bone homeostasis depends on the balance between osteoblasts (cells that build bone) and osteoclasts (cells that resorb bone). When osteoclast activity outpaces osteoblast formation, the result is net bone loss and, eventually, osteoporosis. Auricularia auricula-judae (wood ear mushroom) has emerged as an unexpected candidate in bone research, with two studies demonstrating direct effects on these cell populations and additional studies showing anti-inflammatory effects on cytokines that drive bone resorption. The research is early stage, entirely preclinical, and limited to cell culture and rodent models.

For the broader bone health picture, see wood ear and bone health: osteoporosis research and wood ear and calcium absorption: vitamin D and bone mineral density research. For the postmenopausal context, see black fungus for postmenopausal bone loss.

The Biphasic Bone Effect: One Extract, Two Actions

Kim et al. (2024) published the most mechanistically complete bone study on Auricularia to date, testing a water extract of Auricularia auricula-judae (AAJWE) on both osteoclast and osteoblast cell populations.^[1]

Bone Remodeling — Two Opposing Arms

One Extract, Pushing Both Directions at Once

Bone is continuously torn down by osteoclasts and rebuilt by osteoblasts. Most osteoporosis drugs act on one arm only. In cell culture, a single Auricularia auricula-judae water extract (AAJWE) did both — it blocked the resorption arm at ERK/JNK and amplified the formation arm at Smad/Runx2. The study's authors call this the biphasic effect.

Arm 1 — suppressed^[1]

AAJWE blocks osteoclast formation

The extract inhibits ERK and JNK phosphorylation during RANKL-induced differentiation. With those MAP kinases quiet, the c-Fos/NFATc1 transcriptional program never switches on, and precursor cells fail to fuse into mature bone-resorbing osteoclasts.

RAW 264.7 macrophages + RANKL; TRAP staining showed fewer multinucleated osteoclasts, with no cytotoxicity

Arm 2 — amplified^[1]

AAJWE strengthens osteoblast differentiation

In the presence of BMP-2, the extract induces ALP expression dose-dependently and strengthens BMP-2-induced osteogenesis by activating Runx2 and Smad phosphorylation. It does not replace BMP-2 — it potentiates a bone-formation signal that is already running.

Osteoblast differentiation assay; dose-dependent ALP induction in the presence of BMP-2

Why "biphasic" matters: most osteoporosis drugs are either anti-resorptive (bisphosphonates, denosumab) or anabolic (teriparatide, romosozumab), rarely both. An agent doing both would, in principle, preserve bone quality better than targeting one arm alone. That is the theoretical appeal here — and it is still only theoretical.

Hard limit: both arms were shown in separate cell-culture experiments, not in a living organism where resorption and formation interact dynamically. No bone density was measured. Whether an orally consumed extract reaches bone tissue at the concentrations tested here is unknown, and no human study exists.

Mechanism synthesis; all pathway steps and both directions of effect from Kim et al. 2024 [1]

Osteoclast Inhibition

Using RAW 264.7 macrophage cells stimulated with RANKL (receptor activator of nuclear factor kappa-B ligand, the primary signal that triggers osteoclast formation), the researchers found AAJWE inhibited the formation of multinucleated TRAP-positive osteoclasts without cytotoxic effects. Tartrate-resistant acid phosphatase (TRAP) staining confirmed reduced osteoclast differentiation.

The molecular mechanism involved suppression of c-Fos and NFATc1, two transcription factors essential for osteoclastogenesis. AAJWE achieved this by inhibiting phosphorylation of ERK and JNK, upstream MAP kinases in the RANKL signaling cascade. When ERK and JNK phosphorylation is blocked, the c-Fos/NFATc1 transcriptional program cannot activate, and osteoclast precursor cells fail to differentiate into mature bone-resorbing cells.

Osteoblast Promotion

In the same study, AAJWE exhibited a dose-dependent induction of alkaline phosphatase (ALP) expression in the presence of BMP-2 during osteoblast differentiation. ALP is a marker of osteoblast maturation and mineralization capacity. AAJWE strengthened BMP-2-induced osteogenesis through activation of Runx2, the master transcription factor for osteoblast differentiation, and Smad phosphorylation, the downstream signaling cascade from BMP receptors.

This dual activity is what the authors term "biphasic": the same extract suppresses bone destruction and promotes bone formation simultaneously. Most osteoporosis drugs are either anti-resorptive (bisphosphonates, denosumab) or anabolic (teriparatide, romosozumab), but rarely both. An agent that does both would theoretically maintain bone quality better than targeting one side alone.

The caveat: this is a single cell culture study. No in vivo bone density measurements were performed. Whether the extract reaches bone tissue after oral administration, and whether the concentrations tested in vitro are achievable systemically, remains unknown.

To place the BMP-2/Smad/Runx2 pathway in context: BMP-2 (bone morphogenetic protein 2) is the primary growth factor that initiates osteoblast differentiation from mesenchymal stem cells. It binds cell surface receptors that activate Smad proteins (specifically Smad1/5/8), which translocate to the nucleus and cooperate with Runx2 to turn on bone matrix genes like osteocalcin, collagen type I, and osteopontin. AAJWE did not replace BMP-2 but enhanced its signaling, meaning the extract acts as a potentiator of existing bone formation signals rather than an independent osteogenic agent. This distinction matters: the extract alone would not form bone, but it could theoretically accelerate bone formation where BMP-2 signaling is already active.

On the osteoclast side, the ERK/JNK pathway targeted by AAJWE is shared with the NF-kappaB pathway that several anti-osteoporosis drugs target. Denosumab, a monoclonal antibody used clinically, blocks RANKL directly. AAJWE acts further downstream, blocking the intracellular signaling that RANKL triggers. Whether this downstream inhibition is as effective as blocking RANKL itself at the receptor level is unknown.

The Central Mechanism Study

Kim et al. (2024) · Journal of Microbiology and Biotechnology

Population

Cell culture only — RAW 264.7 macrophages for osteoclast assays, and osteoblast cultures for differentiation assays. No animals, no humans.

Intervention

Auricularia auricula-judae water extract (AAJWE), tested across a dose range

Comparator

RANKL-stimulated and BMP-2-stimulated controls without extract

Finding

TRAP staining showed AAJWE inhibited formation of multinucleated osteoclasts with no cytotoxic effect, reducing RANKL-induced differentiation by inhibiting c-Fos/NFATc1 through suppressed ERK and JNK phosphorylation. In parallel, AAJWE dose-dependently induced ALP expression in the presence of BMP-2 and strengthened BMP-2-induced osteogenesis via Runx2 activation and Smad phosphorylation.

preliminary The biphasic claim rests on two separate cell-culture experiments, not on one living system where resorption and formation interact. The extract is an uncharacterized crude water extract, so the active compounds are unidentified — meaning no one could yet standardize a preparation to reproduce this.

Kim et al., Journal of Microbiology and Biotechnology, 2024; 34(12): 2576-2585

Peptide-Calcium Complex and Disuse Osteoporosis

Qu et al. (2019) took a different approach, preparing a novel Auricularia auricula peptide-calcium complex (AP-Ca) from protein hydrolysates and testing it against disuse osteoporosis.^[2] Disuse osteoporosis affects bedridden patients and astronauts, where the absence of mechanical loading triggers rapid bone loss.

In Vitro Results

AP-Ca increased calcium content (p < 0.05) and alkaline phosphatase activity (p < 0.05) in osteoblasts cultured in a two-dimensional rotating wall vessel, a device that simulates microgravity conditions. AP-Ca also inhibited production of pro-inflammatory factors induced by loss of mechanical stress, with particular reduction of TNF-alpha (p < 0.05).

In Vivo Results

Using a mouse tail suspension model (which removes weight bearing from the hind limbs), AP-Ca improved:

• Bone mineral density
• Bone mineral content
• Bone organic content

AP-Ca also normalized enzymes related to bone metabolism, including alkaline phosphatase (p < 0.05) and serum tartrate-resistant acid phosphatase (p < 0.05). The latter is a marker of osteoclast activity, and its reduction indicates AP-Ca suppressed bone resorption in vivo.

Anti-Inflammatory Gene Regulation

AP-Ca downregulated bone resorption-associated pro-inflammatory genes:

• IL-1 reduced by 59.53 +/- 3.55% (p < 0.05)
• TNF-alpha reduced by 48.01 +/- 5.68% (p < 0.05)
• IL-6 reduced by 40.00 +/- 5.89% (p < 0.05)

Bone Resorption Genes — Tail-Suspension Mice

Three Cytokines Down, IL-1 Furthest

An Auricularia peptide-calcium complex (AP-Ca) downregulated the three pro-inflammatory genes most closely tied to osteoclast-driven bone loss. These are gene expression changes in mice whose hind limbs were unloaded to model disuse osteoporosis — not bone density, and not human data.

IL-1−59.53%largest reduction

Role in bone loss: One of the strongest known stimulators of osteoclast formation. IL-1 drives RANKL expression on osteoblasts, which in turn activates osteoclast differentiation.

TNF-α−48.01%

Role in bone loss: Also drives RANKL expression and amplifies osteoclast activity. This was the cytokine most reduced in the study’s separate cell-culture arm under simulated microgravity.

IL-6−40.00%smallest reduction

Role in bone loss: Promotes osteoclast survival, extending how long each bone-resorbing cell stays active rather than increasing how many form.

How to read it: AP-Ca did not simply blunt one inflammatory signal — it lowered all three of the cytokines that drive bone resorption, hitting the upstream inflammatory drivers rather than only the osteoclast endpoint. The ordering matters too: the deepest cut landed on IL-1, the strongest of the three at stimulating osteoclast formation.

Scope limit: AP-Ca is a processed derivative — enzymatically hydrolyzed Auricularia protein chelated to calcium — not something present in whole wood ear mushrooms. The tail-suspension model also produces a faster, more acute bone loss than postmenopausal or age-related osteoporosis, so these reductions do not transfer automatically to slower, inflammation-driven bone loss.

All three values, spreads and significance levels as reported in Qu et al. 2019 [2]

These three cytokines are central to osteoclast-driven bone resorption. IL-1 and TNF-alpha directly stimulate RANKL expression on osteoblasts, which then activates osteoclast differentiation. IL-6 promotes osteoclast survival. By reducing all three, AP-Ca addresses the inflammatory drivers of bone loss, not just the osteoclast endpoint.

The practical significance: Auricularia-derived peptide-calcium complexes may offer better calcium bioavailability than calcium carbonate supplements (the standard supplement form), because peptide-bound calcium is absorbed through different intestinal transport mechanisms than ionic calcium. Peptide chelation shields calcium ions from precipitation with phosphate and phytate in the intestinal lumen, potentially improving absorption efficiency. The best-characterized precedent is casein phosphopeptides from milk, whose calcium-chelating structure-activity relationships and intestinal absorption mechanisms have been mapped in detail across in vitro and animal work (Liu et al., Critical Reviews in Food Science and Nutrition, 2024). That precedent establishes the mechanism is real in principle; it does not establish that AP-Ca performs comparably, which has never been tested head to head.

The tail suspension model, while validated for studying disuse osteoporosis, creates a more acute bone loss pattern than the gradual resorption seen in postmenopausal osteoporosis or age-related bone loss. AP-Ca's effectiveness in this rapid-loss model does not guarantee effectiveness in slower, inflammation-driven bone loss patterns. The 59.5% reduction in IL-1 gene expression is particularly relevant because IL-1 is one of the strongest stimulators of osteoclast formation, and its persistent elevation in chronic inflammatory conditions (rheumatoid arthritis, inflammatory bowel disease) drives significant secondary bone loss.

Whether AP-Ca can be produced at scale and whether its bone-protective effects are maintained through shelf life and oral delivery are practical questions that remain unanswered. The study used direct administration, bypassing the gastrointestinal degradation that any oral supplement would face.

The Only In Vivo Bone Data

Qu et al. (2019) · Journal of Food Science

Population

Mice in a tail-suspension model of disuse osteoporosis, plus osteoblasts cultured in a rotating wall vessel simulating microgravity

Intervention

Auricularia auricula peptide-calcium complex (AP-Ca), prepared from enzymatic protein hydrolysates chelated with calcium

Comparator

Untreated tail-suspension controls

Finding

AP-Ca improved bone mineral density, bone mineral content and bone organic content, and normalized bone-metabolism enzymes including alkaline phosphatase and serum tartrate-resistant acid phosphatase (both p < 0.05). It downregulated the bone-resorption genes IL-1, TNF-alpha and IL-6 by 59.53 +/- 3.55%, 48.01 +/- 5.68% and 40.00 +/- 5.89% respectively (all p < 0.05).

preliminary Disuse osteoporosis from unloading is a different, faster process than the postmenopausal and age-related bone loss most people are concerned about — this model was not designed to answer that question. AP-Ca is also an industrially processed derivative, not a component of edible wood ear.

Qu et al., Journal of Food Science, 2019; 84(7): 1909-1919

The Inflammation Connection: Gut Microbiota and Bone

Two additional studies from the Auricularia gut microbiome research provide supporting evidence for bone-relevant anti-inflammatory effects.

Shu et al. (2023) demonstrated that Auricularia polysaccharides modulated gut microbiota in NAFLD mice, enriching Lactobacillus and Bifidobacterium while relieving liver injury, inflammation and fibrosis, and maintaining intestinal barrier function.^[3] The reduction in inflammation is relevant to bone because chronic low-grade inflammation (as seen in metabolic syndrome, NAFLD, and aging) is a recognized driver of osteoporosis. The study reported inflammation as a composite outcome, so which individual cytokines fell — and whether they were the ones that matter for bone — is not established from this source.

Xu et al. (2021) showed Auricularia polysaccharides at 50 and 100 mg/kg decreased inflammation and insulin resistance in diabetic mice while reshaping gut microbiota.^[4] Type 2 diabetes itself accelerates bone loss through multiple mechanisms including advanced glycation end-product accumulation, and the anti-inflammatory gut effects could indirectly protect bone tissue.

The gut-bone axis is an emerging research area. Gut bacteria influence bone metabolism through immune modulation, calcium absorption, vitamin K2 production, and systemic inflammation control. It is tempting to close the loop here — Auricularia polysaccharides enrich Lactobacillus, and Lactobacillus supplementation has been tested for bone loss in people — but the human probiotic evidence is genuinely split, and its connection to Auricularia is weaker than it first appears.

The strongest supporting result is a 2024 systematic review and meta-analysis in Frontiers in Endocrinology (Wang et al.), which pooled 12 randomized controlled trials in 1,183 postmenopausal women and found probiotic supplementation associated with greater bone mineral density at both the lumbar spine and hip, with a more pronounced effect in women with osteopenia than in those with established osteoporosis. Against that, the largest and longest trial of the specific strain most associated with bone was null: Gregori et al. (JAMA Network Open, 2024) randomized 239 early postmenopausal women to Limosilactobacillus reuteri ATCC PTA 6475 at two doses or placebo for two years, and found no effect on bone loss or on any bone turnover marker. An earlier trial by Nilsson et al. (Journal of Internal Medicine, 2018) in women aged 75 to 80 with low bone density did find an effect, but a modest one that is worth stating precisely: both groups lost bone over 12 months, and the probiotic group simply lost less (-0.83% versus -1.85% tibia volumetric BMD). That is slowed loss, not gained density.

Two further gaps separate that literature from Auricularia. First, those trials tested one defined bacterial strain at a controlled dose, whereas Auricularia polysaccharides were shown to enrich Lactobacillus at the genus level in mice — a genus contains many strains with different effects, so this is not the same intervention. Second, no study has run the full chain in any species: Auricularia intake, to Lactobacillus enrichment, to a measured bone outcome. For the full gut microbiome evidence, see Auricularia and gut microbiome modulation. For calcium absorption research, see wood ear and calcium absorption: mineral research.

Fact Check

Does the gut-bone axis mean wood ear protects bone through your microbiome?

The claim

“Auricularia feeds Lactobacillus, and Lactobacillus is proven to build bone density in postmenopausal women — so wood ear protects bone through the gut.”

Chaining three separately plausible findings — a mouse prebiotic effect, a named bacterial genus, and human probiotic trials — into a causal sequence none of them tested together

What research shows

Unsupported

Each link is weaker than the chain implies. The human trials used one defined strain (Limosilactobacillus reuteri ATCC PTA 6475), not the Lactobacillus genus that Auricularia enriched in mice. And those trials disagree: a 2024 meta-analysis of 12 RCTs in 1,183 postmenopausal women found a bone density benefit, while the largest and longest single trial of that strain — 239 women over two years — found no effect on bone loss or bone turnover at all.

Even the positive human trial is narrower than it sounds. Nilsson et al. (2018) did not show gained bone density; both arms lost bone and the probiotic arm lost less. Most importantly, no study in any species has tested the actual chain — Auricularia intake, to Lactobacillus enrichment, to a bone outcome. The gut-bone axis is a genuine research area, but here it is a hypothesis, not a finding.

Wang et al., Frontiers in Endocrinology, 2024 (meta-analysis, 12 RCTs); Gregori et al., JAMA Network Open, 2024 (null, n=239, 2 years); Nilsson et al., Journal of Internal Medicine, 2018; gut effects from Shu et al., 2023 and Xu et al., 2021

Limitations and Missing Evidence

The bone research on Auricularia is at the very earliest preclinical stage. The gaps are substantial:

Only two studies directly examine bone cells or bone tissue. Kim et al. (2024) used cell culture only, with no in vivo bone measurements. Qu et al. (2019) included a mouse model but used tail suspension (disuse) rather than the more common ovariectomy model for postmenopausal osteoporosis, the most clinically prevalent form.

No human bone data exist. No clinical trials, no bone density measurements, no fracture outcomes.

The biphasic effect is unconfirmed in vivo. Kim et al. (2024) showed simultaneous osteoclast inhibition and osteoblast promotion in separate cell culture experiments, not in a living organism where the two processes interact dynamically.

Dose and bioavailability are unknown. Whether orally consumed Auricularia compounds reach bone tissue at effective concentrations has not been studied. Many polysaccharides have poor systemic bioavailability, which is why the Kang et al. (2024) nanoparticle delivery work exists.^[5]

The peptide-calcium complex (Qu et al., 2019) is a processed derivative. AP-Ca is not something found in whole wood ear mushrooms. It requires enzymatic protein hydrolysis and calcium chelation, making it closer to a nutraceutical ingredient than a dietary food.

No comparison to established osteoporosis treatments. Neither study compared Auricularia compounds to bisphosphonates, denosumab, or teriparatide. Without such comparisons, the clinical relevance of the observed effects cannot be estimated.

Active compound identification is incomplete. Kim et al. (2024) used a crude water extract containing an uncharacterized mixture of polysaccharides, proteins, and small molecules. Which specific compounds drive the osteoblast-promoting and osteoclast-inhibiting effects has not been determined. Without active compound identification, standardization of effective preparations is impossible.

The two bone studies come from different compound classes. Kim et al. (2024) used a water extract (rich in polysaccharides and water-soluble proteins), while Qu et al. (2019) used enzymatically hydrolyzed peptides complexed with calcium. These are fundamentally different preparations, and their bone-relevant mechanisms may be entirely unrelated. Grouping them under "Auricularia bone effects" is convenient but potentially misleading; they may represent two independent findings rather than converging evidence for a single bone-protective mechanism.

Evidence quality — Auricularia and bone

1. Cell & Lab Studiescompleted

   The biphasic mechanism in culture: osteoclast inhibition via ERK/JNK suppression of c-Fos/NFATc1, and BMP-2-dependent osteoblast promotion via Smad/Runx2 (Kim 2024). AP-Ca raised calcium content and ALP activity in osteoblasts under simulated microgravity (Qu 2019).

2. Animal Studiescurrent

   A single rodent model: AP-Ca improved bone mineral density, mineral content and organic content in tail-suspension mice, and downregulated IL-1, TNF-alpha and IL-6 (Qu 2019). Supporting anti-inflammatory and gut-microbiota effects in NAFLD and diabetic mice (Shu 2023; Xu 2021).

3. Case Reports & Early Seriesmissing

   No case reports or observational series describe bone outcomes in people consuming wood ear or Auricularia preparations

4. Small Human Trialsmissing

   No human trial of any Auricularia preparation has measured a bone endpoint — not bone density, not bone turnover markers, not fracture risk

5. Large Randomized Trialsmissing

   None. No dose-finding, no ovariectomy-model equivalent in humans, no comparison against bisphosphonates or denosumab

6. Meta-Analyses & Systematic Reviewsmissing

   Nothing to pool — with two direct preclinical studies using two unrelated preparations, there is no body of comparable evidence to synthesize

The evidence stops at one rodent study and one cell-culture study, built on two chemically unrelated preparations. The mechanism is unusually well-described for how little total evidence exists, which makes it easy to overrate. Nothing here has been tested in a human being, so 'wood ear supports bone health' is a preclinical hypothesis, not an established effect.

Kim 2024 [1]; Qu 2019 [2]; supporting anti-inflammatory work from Shu 2023 [3] and Xu 2021 [4]

Safety

Moderate

This is preclinical research, not a bone-health protocol

Concern

Osteoporosis is a fracture-risk condition that is diagnosed and monitored with bone density scanning and managed with treatments that have documented fracture-reduction data. Nothing described in this article has been tested in a human being for any bone outcome. The two preparations studied — a concentrated water extract and an industrially produced peptide-calcium complex — are also not what someone eats when they eat wood ear mushrooms, and neither has established human dosing, bioavailability, or safety data for this purpose.

What the research says

Read this as mechanism research that identifies a plausible target, not as evidence of benefit. The honest summary is that Auricularia does something interesting to bone cells in a dish and to bone density in unloaded mice, and that no one knows whether any of it happens in people.

Particularly relevant for: Anyone with osteoporosis, osteopenia, a prior fragility fracture, or elevated fracture risk — and anyone considering substituting a mushroom product for prescribed bone treatment

What to do

This is not medical advice. Do not delay, stop, or substitute prescribed osteoporosis treatment or calcium and vitamin D supplementation based on preclinical mushroom research; discuss bone health and any supplement use with a qualified clinician.

Based on the evidence base described here: Kim et al., 2024 (cell culture) and Qu et al., 2019 (mouse model), with no human bone outcome studies available.

The Bottom Line

Auricularia auricula-judae shows early-stage evidence of bone-relevant biological activity. A water extract simultaneously inhibits osteoclast formation (via ERK/JNK suppression of c-Fos/NFATc1) and promotes osteoblast differentiation (via BMP-2/Smad/Runx2 activation) in cell culture. A peptide-calcium complex improves bone mineral density and reduces pro-inflammatory bone resorption genes (IL-1, TNF-alpha, IL-6) in a disuse osteoporosis mouse model. Supporting anti-inflammatory effects from gut microbiome studies add biological plausibility, though the popular gut-bone chain — Auricularia to Lactobacillus to stronger bone — has never been tested end to end, and the human probiotic trials it borrows credibility from disagree with each other. All evidence is preclinical, from two direct bone studies using two unrelated preparations. No human bone outcomes have been measured.

Frequently Asked Questions

Can wood ear mushroom help with osteoporosis?

Two preclinical studies suggest potential. Kim et al. (2024) showed Auricularia water extract both inhibited bone-resorbing osteoclasts and promoted bone-forming osteoblasts in cell culture. Qu et al. (2019) demonstrated an Auricularia peptide-calcium complex improved bone mineral density in disuse osteoporosis mice. No human osteoporosis studies have been conducted. The evidence is limited to cell culture and a single mouse model, and neither preparation is what you consume when you eat wood ear mushrooms.

How does Auricularia affect osteoblast differentiation?

Auricularia auricula-judae water extract enhanced BMP-2-stimulated osteoblast differentiation by activating the Smad phosphorylation and Runx2 transcription factor pathways in a dose-dependent manner (Kim et al., 2024). Runx2 is the master regulator of osteoblast maturation, controlling expression of bone matrix proteins. Importantly, the extract did not replace BMP-2 — it strengthened a bone-formation signal that was already active, meaning it behaves as a potentiator rather than an independent osteogenic agent. Separately, an Auricularia peptide-calcium complex increased alkaline phosphatase activity in osteoblasts under simulated microgravity (Qu et al., 2019).

Does wood ear mushroom inhibit bone loss?

In cell culture, Auricularia water extract inhibited RANKL-induced osteoclast formation by suppressing ERK and JNK phosphorylation, which blocked the c-Fos/NFATc1 transcription factors essential for osteoclast differentiation (Kim et al., 2024). In a mouse disuse model, an Auricularia peptide-calcium complex reduced serum tartrate-resistant acid phosphatase (a marker of bone resorption) and downregulated IL-1, TNF-alpha, and IL-6 gene expression by 40-60% (Qu et al., 2019). These are laboratory findings, not clinical evidence of bone loss prevention.

Is Auricularia good for calcium absorption?

An Auricularia peptide-calcium complex (AP-Ca) increased calcium content in osteoblasts cultured under simulated microgravity conditions (Qu et al., 2019). Peptide-bound calcium may offer different absorption characteristics than calcium carbonate supplements, potentially using different intestinal transport mechanisms — a chelation strategy best characterized for casein phosphopeptides from milk (Liu et al., 2024). However, no comparative absorption studies between AP-Ca and standard calcium supplements have been conducted in humans. Wood ear mushroom also contains trace minerals naturally, but specific calcium bioavailability data from whole mushroom consumption are lacking.

What is the gut-bone axis and how does Auricularia relate?

The gut-bone axis describes how intestinal bacteria influence bone metabolism through immune modulation, calcium absorption, and systemic inflammation control. Auricularia polysaccharides reshape gut microbiota composition in mice, increasing Lactobacillus and Bifidobacterium while relieving inflammation (Shu et al., 2023; Xu et al., 2021). Since chronic inflammation drives osteoclast activation and bone resorption, reducing systemic inflammation through gut modulation could theoretically protect bone. But this has never been tested in a bone outcome study of Auricularia, and the human probiotic literature it borrows credibility from is itself divided: a 2024 meta-analysis of 12 trials in 1,183 postmenopausal women found a bone density benefit, while the longest single trial of the leading strain found none over two years.

Is there a difference between eating wood ear and taking Auricularia bone supplements?

The two direct bone studies used processed Auricularia preparations, not whole mushroom. Kim et al. (2024) used a concentrated water extract, and Qu et al. (2019) used an enzymatically produced peptide-calcium complex. Whether eating whole wood ear mushroom delivers enough of the active compounds to affect bone metabolism is unknown. The peptide-calcium complex in particular requires industrial processing (protein hydrolysis and calcium chelation) that does not occur during normal food preparation.

Sources & References

1. 1RTHM-00885·Kim, Shin-Hye et al. (2024). “The Biphasic Activity of Auricularia Auricula-Judae Extract on Bone Homeostasis through Inhibition of Osteoclastogenesis and Modulation of Osteogenic Activity..” Journal of microbiology and biotechnology.Study breakdown →PubMed →↩
2. 2RTHM-00584·Qu, Hang et al. (2019). “Anti-Disuse Osteoporosis Activity of a Complex of Calcium-Binding Peptide from Auricularia auricula Protein Hydrolysates..” Journal of food science.Study breakdown →PubMed →↩
3. 3RTHM-00852·Shu, Yifan et al. (2023). “The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism..” International journal of biological macromolecules.Study breakdown →PubMed →↩
4. 4RTHM-00728·Xu, Nuo et al. (2021). “Auricularia auricula-judae (Bull.) polysaccharides improve type 2 diabetes in HFD/STZ-induced mice by regulating the AKT/AMPK signaling pathways and the gut microbiota..” Journal of food science.Study breakdown →PubMed →↩
5. 5RTHM-00883·Kang, Li et al. (2024). “Auricularia auricula Anionic Polysaccharide Nanoparticles for Gastrointestinal Delivery of Pinus koraiensis Polyphenol Used in Bone Protection under Weightlessness..” Molecules (Basel.Study breakdown →PubMed →↩